BC
MLTX icon

BIT Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

BIT Capital’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,610
Closed -$571K – 105
2025
Q1 		$571K Sell
14,610
-6,138
-30% -$264K 0.05% 72
2024
Q4 		$1.12M Buy
+20,748
New +$1.06M 0.09% 68

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BIT Capital's MLTX Position: Q2 2025 in Review

BIT Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 14,610 shares — an estimated $571K sold.

BIT Capital first reported a position in MLTX in Q4 2024 and held it in 2 quarters. The position peaked at $1.12M in Q4 2024. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

  • BIT Capital reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
  • BIT Capital sold 14,610 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $571K.
  • BIT Capital first reported a position in MoonLake Immunotherapeutics in Q4 2024 and held it in 2 quarters.
  • BIT Capital's MoonLake Immunotherapeutics position peaked at $1.12M in Q4 2024.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on BIT Capital's 13F filing for Q2 2025, filed 8 Aug 2025.